<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate frequency and clinical features of <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> (HM) after autologous and allogeneic stem cell transplantation, protective and therapeutic methods, efficiency of CMV hyperimmune immunoglobulin cytotest (Biotest Pharma) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: The trial enrolled 22 patients (group 1) with HM and severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> after allogeneic bone marrow transplantation, 58 patients (group 2) with HM after autologous stem cell transplantation </plain></SENT>
<SENT sid="2" pm="."><plain>The patients were examined for <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> by serologic methods and PCR </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The probabilities of <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> were greater in group 1 than group 2--10/22(45%) versus 12/58 (21%), p &lt; 0.05 </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical signs of CMV disease were <z:e sem="disease" ids="C0032285" disease_type="Disease or Syndrome" abbrv="PNEUM">pneumonitis</z:e> (27%), <z:hpo ids='HP_0012115'>hepatitis</z:hpo> (32%), <z:e sem="disease" ids="C0017160" disease_type="Disease or Syndrome" abbrv="">gastroenteritis</z:e> (9%), <z:e sem="disease" ids="C0085692" disease_type="Disease or Syndrome" abbrv="">haemorrhagic cystitis</z:e> (55%), slow engraftment (59%), prolonged <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (68%), <z:hpo ids='HP_0002383'>encephalitis</z:hpo> (5%) </plain></SENT>
<SENT sid="5" pm="."><plain>Six (60%) patients with <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> after allogeneic and 1(8%) patient with <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infections</z:e> after autologous stem cell transplantation were dead </plain></SENT>
<SENT sid="6" pm="."><plain>The cytotest after allogeneic transplantation of the bone marrow reduced the risk of <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> from 62 to 36% </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> influences prognosis both in allogeneic and autologous transplantation of hemopoietic stem cells </plain></SENT>
<SENT sid="8" pm="."><plain>Cytotest lowers the risk of CMV development after transplantation of allogeneic bone marrow </plain></SENT>
</text></document>